At the time of writing, Moderna Inc [MRNA] stock is trading at $27.35, down -1.44%. An important factor to consider is whether the stock is rising or falling in short-term value. The MRNA shares have gain 4.71% over the last week, with a monthly amount glided 7.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Neutral rating and assigned the stock a price target of $40. Previously, Barclays downgraded its rating to Equal Weight on February 18, 2025, and dropped its price target to $45. On January 29, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $51 on the stock. Argus downgraded its rating to a Hold. Berenberg started tracking with a Hold rating for this stock on November 19, 2024, and assigned it a price target of $42. In a note dated November 18, 2024, HSBC Securities upgraded an Buy rating on this stock but restated the target price of $58.
For the past year, the stock price of Moderna Inc fluctuated between $23.15 and $150.74. Currently, Wall Street analysts expect the stock to reach $47.5 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $27.35 at the most recent close of the market. An investor can expect a potential return of 73.67% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
According to Moderna Inc [NASDAQ:MRNA], the company’s sales were 3.18B for trailing twelve months, which represents an -35.33% plunge. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -1.08%, and Net Profit Margin reading is -1.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.3 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Moderna Inc [NASDAQ:MRNA] has a current ratio of 4.22. On the other hand, the Quick Ratio is 4.14, and the Cash Ratio is 1.01. Considering the valuation of this stock, the price to sales ratio is 3.33, the price to book ratio is 1.05.
Transactions by insiders
Recent insider trading involved Hussain Abbas, Director, that happened on Jun 11 ’25 when 312.0 shares were sold. Director, Hussain Abbas completed a deal on Jun 11 ’25 to buy 312.0 shares. Meanwhile, Chief Executive Officer Bancel Stephane bought 0.16 million shares on Mar 03 ’25.
